

In the Claims:

Please cancel claims 1-5 and 13-41 and 43-49 without prejudice and replace with new claims 54-67 as follows:

54. A fusion protein comprising an antigen or antigenic portion thereof, and a stress protein or a portion of the amino acid sequence of the stress protein, wherein the stress protein or portion thereof is able to induce a cell mediated cytolytic immune response against the antigen.

55. The fusion protein of claim 54 wherein the antigen is selected from the group consisting of a viral antigen, a tumor associated antigen and an allergen.

56. The fusion protein of claim 54 wherein the antigen is an antigen of the influenza virus.

57. The fusion protein of claim 56 wherein the antigen of the influenza virus is selected from the group consisting of hemagglutinin, nucleoprotein, neuraminidase, M1, M2, PB1, PB2, PA and a combination thereof.

58. The fusion protein of claim 54 wherein the fusion protein is selected from the group consisting of pET65MP/NP-B and pET65M/NP-D.

59. The fusion protein of claim 54 wherein the antigen includes a cytolytic T cell epitope.

60. The fusion protein of claim 54 wherein the antigen is selected from the group consisting of MAGE1, MAGE3, BAGE, GAGE, Tyrosinase, MART-1, gp100, pg75, MUM-1, HER2/neu, MUC-1, human papilloma virus proteins E6 and E7, GpT-V, beta-catenin, CDK4 and p15.

60
61. The fusion protein of claim 54 wherein the stress protein is a bacterial stress protein.

62. The fusion protein of claim 61 wherein the stress protein is a mycobacterial stress protein.

63. The fusion protein of any one of claims 54-62 in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle.

64. A method of inducing a cell mediated cytolytic immune response against an antigen, comprising administering to a vertebrate in an amount effective to induce the immune response a fusion protein according to claim 54.

65. The method of claim 64 wherein the fusion protein is in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle.

66. The method of claim 64 with the fusion protein of any one of claims 54-61
58-62.

67. The method of claim 66 wherein the fusion protein is in combination with a pharmaceutically acceptable excipient, carrier, diluent or vehicle. —